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Summary
Retrospective analysis
revealed a vertebral
compression fracture (VCF)
rate of 11.9% (8.4% with
exclusion of patients undergoing surgical fixation) from
a total of 1070 vertebral
bodies (448 patients) who
received spine stereotactic
radiosurgery (SRS) at our
institution. Patients with a
previous VCF, primary hematologic malignancies, tumors located in thoracic
spine, and lytic lesions had
increased rates of developing
a VCF. Single-fraction SRS
doses of 16 to 18 Gy to the

Purpose: To determine our institutional vertebral compression fracture (VCF) rate after spine stereotactic radiosurgery (SRS) and determine contributory factors.
Methods and Materials: Retrospective analysis from 2001 to 2013 at a single institution was performed. With institutional review board approval, electronic medical records of 1905 vertebral bodies from 791 patients who were treated with SRS for the
management of primary or metastatic spinal lesions were reviewed. A total of 448 patients (1070 vertebral bodies) with adequate follow-up imaging studies available were
analyzed. Doses ranging from 10 Gy in 1 fraction to 60 Gy in 5 fractions were delivered. Computed tomography and magnetic resonance imaging were used to evaluate
the primary endpoints of this study: development of a new VCF, progression of an
existing VCF, and requirement of stabilization surgery after SRS.
Results: A total of 127 VCFs (11.9%; 95% confidence interval [CI] 9.5%-14.2%) in
97 patients were potentially SRS induced: 46 (36%) were de novo, 44 (35%) VCFs
progressed, and 37 (29%) required stabilization surgery after SRS. Our rate for radiologic VCF development/progression (excluding patients who underwent surgery) was
8.4%. Upon further exclusion of patients with hematologic malignancies the VCF rate
was 7.6%. In the univariate analyses, females (hazard ratio [HR] 1.54, 95% CI 1.012.33, PZ.04), prior VCF (HR 1.99, 95% CI 1.30-3.06, PZ.001), primary hematologic malignancies (HR 2.68, 95% CI 1.68-4.28, P<.001), thoracic spine lesions (HR
1.46, 95% CI 1.02-2.10, PZ.02), and lytic lesions had a significantly increased risk
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spine seem to be associated
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for VCF after SRS. On multivariate analyses, prior VCF and lesion type remained
contributory.
Conclusions: Single-fraction SRS doses of 16 to 18 Gy to the spine seem to be associated with a low rate of VCFs. To the best of our knowledge, this is the largest reported experience analyzing SRS-induced VCFs, with one of the lowest event rates
reported. Ó 2016 Elsevier Inc. All rights reserved.

Introduction
Metastatic involvement of the vertebral bodies is often seen
in patients with advanced-stage cancers. A majority of
these patients present with pain and occasionally neurologic compromise. Standard external beam radiation therapy has been used extensively in this situation, with good
symptom control with minimal toxicity. However, because
of the nonconformal nature of these treatment plans, surrounding normal tissues receive a significant amount of
dose. With the development of better immobilization,
treatment planning techniques, and image verification, the
use of stereotactic radiosurgery (SRS) in cases of vertebral
body metastases has increased. This allows for the delivery
of highly conformal radiation to lesions of the spine while
minimizing the amount that reaches surrounding healthy
tissue (1-5). With worldwide cancer rates increasing, and
more than 30% of all cancer patients developing spinal
metastasis (6, 7), the role of SRS will likely increase (8-10).
Two major potential complications are of concern with this
technique of delivering high dose per fraction radiation. One
initial concern was the likely neurologic complication of spinal
cord myelopathy. However, multiple studies have shown that
spine SRS is a safe technique, with low risk of myelopathy as
long as recommended dose constraints are met (4). The second
complication, vertebral compression fractures (VCFs), has also
been described in the literature as an SRS-related complication
(1, 11-16). Vertebral compression fractures can significantly
impact the quality and duration of patients’ lives by causing
severe pain and neurologic deficits (17, 18).
The factors contributing to the development of VCF are
still not completely understood, and thus clinicians are
presented with a challenge when selecting suitable candidates for spine SRS. Our retrospective analysis was performed to determine the rate of VCFs in our institution and
to elucidate some of the factors that might increase the risk.

Methods and Materials
Patient selection and endpoints
Seven hundred ninety-one patients (1905 vertebral bodies)
were treated with SRS for the management of their primary or
metastatic spinal lesions at our institution between June 2001
and December 2013. All patients were presented and discussed in a multidisciplinary spine tumor board attended by
radiation oncologists, neurosurgeons, neuroradiologists, and

medical oncologists. All treatment decisions and recommendations, including whether a patient was a suitable candidate
for spine SRS, were made according to consensus opinions.
Patients had vertebral body metastases from C1 to the sacrum.
Patients who had up to 3 separate areas of involvement and a
maximum of 3 contiguous vertebral bodies were treated using
SRS. In cases in which the metastatic involvement of the
vertebral bodies exceeded these limits, standard fractionated
external beam radiation therapy was delivered. Because there
is no well-accepted universal definition of VCFs after spine
SRS, we relied on the neuroradiologists’ report and multidisciplinary spine tumor board discussion to assess for the presence of new fractures or progression of existing fractures. All
patient images were reviewed by neuroradiologists at our
institution, vertebral body heights were measured in every
spine image series, and a VCF was classified as any measurable height loss noted on a vertebral body compared with prior
imaging. The patient images were then subsequently reviewed
at a multidisciplinary tumor board to determine fracture progression and treatment indications.
We analyzed data from 448 patients (1070 vertebral
bodies) who had follow-up imaging studies available at our
institution for review. One hundred ninety-seven patients
were lost to follow-up, 117 died within 3 months of receiving
SRS, and 29 were patients referred from outside facilities for
SRS (Fig. E1, CONSORT diagram; available online at www.
redjournal.org). Electronic medical records of these patients
were retrospectively reviewed in this institutional review
boardeapproved study. Computed tomography and magnetic resonance imaging were used to evaluate the primary
endpoint. Consistent with prior reports, our events were the
development of a new VCF and the progression of an existing
VCF (11-15). Additionally, we included pre-existing VCFs
that required stabilization surgery beyond 1 week after SRS
as an event. To be classified as an event, the VCF development/progression or stabilization surgery must have occurred
within vertebral bodies treated with SRS. To distinguish
between VCFs caused by tumor progression as opposed to
SRS, VCFs that developed or progressed concurrently with
tumor progression were not included as events. Vertebral
bodies that underwent stabilization surgery before SRS were
excluded from the analysis.

Potential contributing factors
Factors considered included the spinal instability neoplastic
score (SINS) criteria (19) previously found to correlate with
VCF risk: lesion type (12-15), spinal alignment (12, 14),
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Table 1

Fracture rates for demographic, tumor, and dosimetric factors
Variable

Age category (y)
<40
40-49
50-59
60-69
70-79
80þ
Sex
Female
Male
Ethnicity*
Caucasian
African American
Other
Primary tumor location
Breast
Hematologic
Lower gastrointestinal
Lung
Prostate
Othery
Unknown
Previous VCF
Yes
No
No. of levels
1
2
3þ
Prior RT
Yes
No
Lesion type
Blastic
Lytic
Mixed
Unknown
Dose per fraction
15
16
18
>18
Tumor volume (cm3) (missing information
for nZ191 vertebral levels)
<30
30-<50
50-<80
80þ

No. (%) of
patients

No. of fractures
(nZ127)

Total no. of vertebral
levels (nZ1070)

% With fractures

(4)
(10)
(26)
(31)
(22)
(8)

1
14
42
35
28
7

45
113
268
350
218
76

2
12
16
10
13
9

202 (45)
246 (55)

68
59

462
608

15
10

250 (57)
163 (37)
22 (5)

73
45
7

596
395
51

12
11
14

79
55
26
96
62
103
27

26
29
6
26
7
28
5

212
115
51
190
174
248
80

12
25
12
14
4
11
6

73
54

446
624

16
9

74
47
6

488
379
203

15
12
3

10
117

116
954

9
12

16
57
31
23

231
294
220
325

7
19
14
7

10
42
73
1

139
314
577
31

7
13
13
3

23
28
32
24

239
226
195
219

10
12
16
11

17
44
117
138
97
35

(18)
(12)
(6)
(21)
(14)
(23)
(6)

Abbreviations: RT Z radiation therapy; VCF Z vertebral compression fracture.
* Thirteen missing ethnicity information.
y
Includes bladder (nZ5), bone (nZ8), gynecologic (nZ9), head and neck (nZ7), kidney (nZ19), liver (nZ10), muscle (nZ1), nervous system
(nZ16), pancreas (nZ3), skin (nZ4), thymus (nZ1), thyroid (nZ10), and upper gastrointestinal (nZ10).

and presence of a pre-existing VCF (11, 12, 14). The SINS
classification for spine type (junctional, mobile, semi-rigid,
rigid) was also considered (19). Consistent with prior reports (11-15), bisphosphonate use, histology, dose/fraction,

number of vertebral levels in treatment target, additional
radiation to spine, spine tissue involvement (eg, paraspinal,
epidural, intradural), spine level (cervical, thoracic, lumbar,
sacral), sex, and age were considered. Additionally, the use
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Procedure
The Novalis system (Brainlab, Munich, Germany) was used
for spine SRS. Patient immobilization was achieved with
the aid of vacuum bags. A contrast-enhanced simulation
computed tomography scan with a slice thickness of 3 mm
was performed with infrared fiducial markers (ExacTrac,
Brainlab). These images were fused with diagnostic
T1- and T2-weighted magnetic resonance images in the
treatment planning system to define the target volume,
consisting of the gross tumor and the involved vertebral
body. No expansion margin was added to the gross tumor,
and thus the gross tumor volume (GTV) was equal to the
planning target volume. T2-weighted magnetic resonance
images were used to delineate the spinal cord 6 mm above
and 6 mm below the defined GTV. A spinal cord planning
organ at risk volume was not constructed. Multiple
coplanar intensity modulated radiation beams were used to
optimize the radiation dose to the target volume and
minimize the dose to surrounding tissue. All doses were
prescribed to the 90% isodose line. The primary dose
constraint for plan selection was to achieve the objective of
10 Gy to 10% of the partial volume of the spinal cord and a

Standard VCF
Event
7.6%
8.4%

10.3%
11.9%

Surgical
Events

Hematological
Events

Fig. 1.
(VCF).

Crude rates of vertebral compression fracture

of antiangiogenic therapy, tumor volume, bone disease (eg,
osteoporosis, spondylosis), and ethnicity were looked at as
potential contributing factors.

A
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Fig. 2. Competing risk cumulative incidence functions for vertebral compression fracture (VCFs) based on (A) lesion type,
(B) number of vertebral levels treated, (C) prior VCF, and (D) gender. Abbreviation: SRS Z stereotactic radiosurgery.
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Table 2 Hazard ratios and confidence intervals from the Fine-Gray model using competing risk methods for significant factors in the
univariate and multivariate analyses
Univariate
Variable

HR (95% CI)

Prior VCF
Sacrum spine
Cervical spine
Lesion type
Lytic vs blastic
Mixed vs blastic
Unknown vs blastic
Lytic vs mixed
Unknown vs mixed
Lytic vs unknown
No. of vertebral levels
3þ vs 1
3þ vs 2
2 vs 1
Female
Thoracic spine
Rigid spine type
Primary tumor origin*
Breast
Hematologic
Lower gastrointestinal
Lung
Prostate
Other
Unknown

1.99 (1.30-3.06)
0.22 (0.07-0.71)
0.42 (0.19-0.95)

Multivariate
P
.001
.01
.03

HR (95% CI)

P

1.69 (1.11-2.59)
0.30 (0.10-0.91)
0.41 (0.18-0.94)

.01
.03
.03

3.07
2.01
1.08
1.53
0.54
2.85

(1.52-6.21)
(0.93-4.32)
(0.50-2.33)
(0.89-2.63)
(0.29-1.01)
(1.63-4.97)

.001
.07
.85
.12
.05
<.001

3.04
1.95
1.22
1.56
0.63
2.49

(1.49-6.18)
(0.89-4.28)
(0.54-2.74)
(0.92-2.63)
(0.33-1.18)
(1.43-4.34)

.002
.09
.63
.09
.14
.001

0.19
0.24
0.79
1.54
1.54
0.11

(0.08-0.43)
(0.10-0.56)
(0.53-1.18)
(1.01-2.33)
(1.07-2.21)
(0.02-0.77)

<.001
.001
.25
.04
.02
.02

0.23 (0.10-0.53)
0.25 (0.11-0.61)
0.90 (0.60-1.35)

<.001
.002
.61

1.02
2.68
1.08
1.22
0.28
0.93
0.49

(0.59-1.75)
(1.68-4.28)
(0.40-2.94)
(0.73-2.08)
(0.11-0.72)
(0.58-1.50)
(0.19-1.27)

.94
<.001
.88
.43
.008
.75
.14

Abbreviations: CI Z confidence interval; HR Z hazard ratio. Other abbreviation as in Table 1.
* Hazard ratio for specific locations compared with all other tumor locations.

maximum point dose of 14 Gy. In cases in which this
constraint was not achievable, under-dosage to the GTV
was accepted to meet the above dosimetric objective. Prescribed dose did not vary on the basis of the presumed
radio-resistance of the histopathology. This procedure has
been detailed in previous reports (2, 20, 21).

censored. Kaplan-Meier estimates were used to compute
the cumulative incidence rates for survival. All testing was
2-sided, and a was set at 0.05. SAS version 9.4 (SAS
Institute, Cary, NC) was used for the analyses.

Results
Statistics
Descriptive statistics were used to describe the demographic and histologic factors. Death before a fracture
was considered a competing risk to fracture. Competing
risk analyses using the Fine and Gray method were done to
assess the univariate and multivariate relationship between
the demographic, tumor, and dosimetric factors and time to
VCF. In addition, the robust sandwich covariance matrix
for computing the standard errors was used to take into
account the possibility of multiple levels and treatments
within a patient. The factors considered in the multivariate
analyses were those that were significant in the univariate
analyses. Cumulative incidence functions (CIFs) for VCF
were computed using the competing risk models. For survival analyses, the time variable was computed as the difference between the date of first SRS and date of death or
last contact. Patients still alive at last contact were

Of the 448 patients included in this analysis, 246 (55%)
were males, 250 (57%) were Caucasian, and the mean age
at first SRS was 62.5 years (range, 17-92 years). Twentyone percent of the patients had lung cancer as their primary
tumor location, 18% had breast, 14% had prostate, and 12%
had hematologic primaries (Table 1).
Three hundred ten patients (69%) died during follow-up.
The 1- and 2-year survival rates were 60.5% (95% CI
55.6%-65.4%) and 40.4% (95% CI 35.7%-45.9%),
respectively. Median survival time was 17.7 months (95%
CI 14-20.1 months). Follow-up imaging in this group of
patients ranged from 1 follow-up magnetic resonance
image done approximately 6 weeks after SRS to 25 images
done up to 7 years after SRS, with a median of 11 follow-up
images up to 22 months.
On the basis of our expanded definition of events (new
VCFs, progressing VCFs, and surgical events), we noted
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127 (11.9%, 95% CI 9.5%-14.2% [crude rate]; 13.2%, 95%
CI 11.3%-15.5% [CIF]) VCFs during follow-up. Of these,
46 (36%) were de novo, 44 (35%) were VCFs that progressed, and 37 (29%) vertebral bodies required stabilization surgery beyond 1 week after SRS. Of these 37, 11
vertebral bodies underwent vertebroplasty, 10 had ballon
kyphoplasty, and the remaining had other surgical instrumentation/fixation procedures. Vertebral compression
fracture due to tumor progression was noted in 62 bodies
out of the 1070 vertebral bodies treated.
When calculating the rate of VCFs excluding patients
classified as surgical events (not described in other published reports), our VCF rate was as follows: 8.4% (95%
CI 6.4-10.4) (crude rate), 9.6%, (95% CI 7.8%-11.7%)
(CIF) (11, 12, 14-16, 22, 23). Upon further exclusion of
patients with hematologic malignancies, the VCF rate was
as follows: 7.6% (95% CI 5.6%-9.7%) (crude rate), 8.7%
(95% CI 7.1%-10.6%) (CIF) (Fig. 1). Among the vertebral
bodies with a VCF, the median time to VCF was
2.7 months, with a range from 5 days to 54.9 months.
Sixty-six percent occurred within the first 6 months. The
1- and 2-year cumulative incidence rates of VCF using the
competing risk estimates were 9% (95% CI 7.3%-11.1%)
and 11.2% (95% CI 9.4%-13.3%), respectively. Excluding
only the hematologic malignancy group, there were 98
VCFs with a corresponding event rate of 10.3% (95% CI
7.9%-12.6%) (crude rate) and 11.4% (95% CI 9.6%13.5%) (CIF) (standard inclusion criteria plus surgical
fixation patients).
The VCF rates for the demographic, tumor, and dosimetric factors can be found in Table 1. In the univariate
analyses, females, prior VCF, primary hematologic malignancies, and thoracic spine and lytic lesion types had a
significantly increased risk for VCF after SRS (Fig. 2 and
Table 2). Prostate tumors, sacrum and cervical spine, three
or more treated levels, and rigid spine type were associated
with a decreased risk of VCF (Table 2). The associations of
VCF after SRS with age, ethnicity, prior radiation therapy,
epidural tissue involvement, paraspinal tissue involvement,
use of bisphosphonates and anti-angiogenesis medications,
other bone disease, dose per fraction, and tumor volume
were not significant (P>.10 for all). On multivariate analyses, prior VCF, sacrum and cervical spine, number of
treated levels, and lesion type (Table 2) remained
significant.
One patient experienced symptoms of radiation
myelopathy that was confirmed on magnetic resonance
imaging. This patient had a diagnosis of breast cancer and
was treated to the cervical spine with a dose of 30 Gy in 10
fractions at an outside institution, followed by 16 Gy reirradiation to the C1 vertebral body owing to tumor progression with epidural extension. The patient underwent
surgical fixation 1 month after SRS because of instability.
She developed quadriplegia approximately 7 months after
the SRS treatment and died after a further 10 months with
progressive metastatic disease.
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Discussion
We analyzed our patient cohort to determine the incidence
and risk factors for SRS-induced VCFs. To the best of our
knowledge this is the largest reported experience, with one
of the lowest rates of VCF. Our overall incidence with our
expanded inclusion criteria (inclusion of surgical events)
was 11.9% and 10.3% with the exclusion of patients with
hematologic malignancies. Upon exclusion of patients undergoing stabilization surgery, these rates were 8.4% and
7.6%, respectively, with the inclusion and exclusion of
patients with hematologic malignancies. The surgical event
was initially included in our analysis to err on the side of
caution and overestimate our fracture rate. A majority of
these patients were symptomatic after SRS but did not have
definitive imaging to confirm a new or existing fracture. In
reality not all of these patients would have in fact had a true
VCF according to imaging studies; therefore we have
provided a rate with exclusion of these events to be more
indicative of our true institutional VCF rate. With our data
being a single institutional experience, all clinical practices
were consistent during the 13-year period. Factors
contributing to VCFs on multivariate analysis were previous VCF and lytic lesions.
The median time to VCF was 2.7 months, with a majority (66%) occurring within the first 6 months. With the
exception of Memorial Sloan-Kettering Cancer Center
(median 25 mo) (13), this is consistent with other reports
indicating that VCFs caused by SRS are more often acute
or subacute complications (Table 3) (12, 13, 21).
Of the 3 SINS criteria previously found to correlate with
SRS-induced VCFs, our results supported having a prior
VCF and a lytic lesion type. We did not find spinal alignment to be related to SRS-induced VCFs; however, SINS
may still have some clinical value in identifying patients
who may be at a higher risk of incurring a VCF.
A majority of the hematologic malignancies in this study
were multiple myeloma. We have previously reported on
our institutional experience with treating multiple myeloma
involving the vertebral bodies with SRS (24). The natural
course of multiple myeloma typically yields numerous
VCFs throughout the patient’s spine at both treated and
untreated levels, thus making it difficult to distinguish between pathologic and SRS-induced fractures (25, 26).
A majority of our VCFs occurred in the thoracic spine
owing to the high incidence (70%) of metastases in this
location (27). Female patients were found to be at an
increased fracture risk. Although previous reports have not
supported this finding, the result seems plausible because
females at baseline have approximately twice the risk of
developing a VCF compared with males. Furthermore, 25%
of postmenopausal women develop VCFs, and with a majority of our patients being at postmenopausal ages, their
lower bone density would likely increase their susceptibility to radiation-induced bone damage (28).
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Table 3
rates

Table summarizing large radiation therapy and stereotactic radiosurgery spinal series reporting vertebral compression fracture
Total patients
(evaluable)

Total vertebral bodies (evaluable)

Follow-up (mo),
median (range)

Overall
survival (mo)

275 (209 evaluable)

NR

49 (13-88)

6

Chow et al, 2007, University of
Toronto
Stereotactic radiosurgery
Rose et al, 2009, MSKCC

3508 (1776
for single-fx RT)

NR

NR

NR

62

71

13

NR

Boehling et al, 2012, MDACC

93

123

14.9 (1-71)

252

410

11.5 m

Cunha et al, 2013, University of
Toronto

90

167

7.4

NR

Sung et al, 2014, KCCH

72

NA

11 (mean)

NA

Thibault, 2014, Sunnybrook Odette
Cancer Centre

37

71

12.3 (1.2-55.4)

Guckenburger, 2014, University of
Würzburg
Germano et al, 2015, Mount Sinai

301

387

11.8

19.5

79

143

16

NR

Jawad et al, 2016, Oakland University
William Beaumont School of
Medicine

541

594

Study
Radiation therapy
Marzano et al, 1995, University
School of Medicine, Perugia, Italy

Sahgal et al, 2013, MDACC,
Cleveland Clinic, University of
Toronto

Present study

791 (448)

1905 (1070)

NR

16

18

8.8 (0-57)

NR

17.7

10.2

Abbreviations: fx Z fraction(s); EQD2 Z equivalent dose in 2 Gy fractions; KCCH Z Korea Cancer Center Hospital; MDACC Z MD Anderson
Cancer Center; MSKCC Z Memorial Sloan-Kettering Cancer Center; M/V Z multivariable analysis; NA Z not applicable; NR Z not reported;
RT Z radiation therapy; SBRT Z stereotactic body radiation therapy; U/V Z univariate analysis; VCF Z vertebral compression fracture.
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Table 3 Table summarizing large radiation therapy and stereotactic radiosurgery spinal series reporting vertebral compression fracture
rates (continued)
Dose (Gy) per fraction (fx)

Fracture no. (%)

Significant U/V factors

Significant M/V factors

3-30 Gy in 10 fx;
30 Gy/8 fx (15 Gy/3 fx,
15 Gy/5 fx)
16 Gy/2 fx
NR

65 (31)

NR

NR

<5%

NR

NR

24 Gy/1 fx

27 (39)

NR

Median doses of:
18 Gy/1 fx
27 Gy/3 fx
30 Gy/5 fx

25 (20)

24 Gy/1 fx

57 (14)

24 Gy/2 fx

19 (11)

 Spinal misalignment
 Lesion type (lytic)
 Degree of pre-existing VCF

18-45 Gy/1-5 fx

26 (36)

 Spinal defomity
 Whole vertebral body

 CT appearance
 Lesion location
 Percent vertebral body
involvement











Age >55 y
Pre-existing fracture
Baseline pain
Narcotic use before and after SBRT
Dose per fraction
Pre-existing VCF
Lesion type (lytic)
Spinal deformity/misalignment
Paraspinal/epidural extension

 Age >55 y
 Preexisting fracture
 Baseline pain












Dose per fraction
Pre-existing VCF
Lesion type (lytic)
Spinal deformity/
misalignment
Paraspinal/epidural extension
Spinal misalignment,
Lesion type (lytic)
Dose per fraction 20 Gy
Lung primary
Hepatocellular primary
Vertebral body osteolysis rate

involvement

 Vertebral body osteolysis rate
24 Gy/2 fx

10 (16)

NR

 Single-fraction SBRT
 Pre-existing VCF

24 Gy/3 fx
Range, 8-60 Gy/1-20 fx
18 Gy/1 fx
Range, 10-18 Gy/1 fx

30 (7.8)

NR

 NR

30 (21)

 NR

Median, 20 Gy/1 fx
Range, 8-40 Gy/1-5 fx

5.7%







18 Gy/1 fx

1279 (11.9)
Adjustment for hematologic
malignancies, 97 (9.9)












Colorectal primary
Pre-existing VCF
Severe pain
SBRT <36.8 days after diagnosis
No additional bone
metastases
No prior chemotherapy
Pre-existing VCF
Tumor volume 37.3 cm3
EQD2 tumor 41.8 Gy
EQD2 spinal cord Dmax 46.1 Gy
Pre-existing VCF
Hematologic primary
Thoracic spine tumors
Lytic lesion
Female patients

 Pre-existing VCF
 No additional bone
metastases

 38.4 Gy prescribed to the target
volume

 Pre-existing VCF
 Lytic lesions
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Patients with prostate cancer were at a significantly
lower risk of developing a VCF. Although the spine is a
common site of metastasis for prostate cancer (29, 30), its
typical slow and less aggressive nature, coupled with
the tendency to form blastic lesions may explain the lower
fracture rate (31). Another variable correlating with
decreased risk of VCF was receiving SRS to 3 or more
vertebral levels. The irradiation of multiple levels in the
spine could potentially result in a balancing of the mechanical load on the spine if multiple levels are treated at
once (32). Both the cervical spine and sacrum were found
to be associated with a decreased fracture risk. This was
expected in the sacrum owing to its fused and rigid nature,
and was likely found in the cervical spine owing to the
significantly lower loads of weight placed on the cervical
vertebrae. Similar to prior reports (11-14), bisphosphonates
were not shown to be protective against SRS-induced
VCFs. Although we postulated that antiangiogenic therapy may potentiate damage to bone marrow within the
spine, no correlation was shown between use and VCF
risk (33).
With regard to the association of dose per fraction and
risk of subsequent VCF, others reported that the risk increases significantly upon dose escalation above 19 Gy
(Table 3) (12, 14). Our results do not directly address this
issue due to the fact that 97% of our patients were treated
with 18 Gy or less. However, this may be one of the main
reasons our fracture rate is one of the lowest reported; doses
over 18 Gy were seldom used. Using doses over 18 Gy to
the spine has been shown to carry an increased risk for
adverse events (12, 14, 34, 35). Table 3 summarizes a
number of large radiation therapy/SRS spinal series
reporting on VCF rates. The Memorial Sloan-Kettering
Cancer Center was the first institution to report on the
rate of SRS-induced VCF finding that 27 (39%) of 71
treated spinal levels developed a VCF (13). Reports by the
MD Anderson Cancer Center (11), the University of Toronto (12), and the Korea Cancer Center Hospital (15) found
the rate to be 11%, 20%, and 36%, respectively. One of the
largest reports pooled data from the MD Anderson Cancer
Center, Cleveland Clinic, and University of Toronto for a
total of 252 patients with 410 treated vertebral bodies, and
found the rate to be 14% (14). A study by Mount Sinai
evaluated single-fraction SRS constrained to 18 Gy or less,
but surprisingly had a fracture rate of 21% (22). A recent
study by Jawed et al (23) was a multi-institutional study
that included a total of 594 vertebral bodies and displayed a
fracture rate of 5.7%. The previous major studies reported
rates of the development or progression of a VCF. Our rate
for radiologic VCF development/progression (excluding
patients who underwent surgery) was 8.4%. Instead of
solely calculating VCF development/progression, our study
calculated an event rate and has accounted for all potential
SRS-induced spinal instability by also including in our rate
the need of stabilization surgery after SRS likely due to an
impending fracture. Other reports did not consider this
finding. In reality not all cases of stabilization surgery
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would be a result of an SRS complication, thus by
including these as events we are potentially over-estimating
our event rate.
This study is limited in that it is a retrospective analysis.
Because of the subjective nature of obtaining Karnofsky
performance status scores and pain scores from a retrospective chart analysis, we did not evaluate these variables.
However, previous reports have not suggested that any
relationship exists between either of these variables. As
shown in Figure E1 (available online at www.redjournal
.org), not all treated patients were evaluable for the purposes of this study. Finally, our study did not evaluate radiation myelopathy, another significant complication of
spine SRS, owing to its rarity, with rates being reported at
<5% (22). A currently ongoing prospective Radiation
Therapy Oncology Group study (protocol 0631) may
address some of these limitations of a retrospective
analysis.
Despite the limitations of this study, strengths such as
the diverse ethnicities and histologies in our patient population add to the clinical utility of our findings. We had 38%
African Americans, 5% other ethnicities, and varied histologies, including multiple myeloma, making ours one of
the few institutions that has reported its findings on spine
SRS for this histology. Another strength of this study is that
all patients were treated using standardized institutional
protocols for treatment planning, immobilization, dose
fractionation, and follow-up. Having a homogenous treatment population allows our results to eliminate these variables from consideration and focus on other potential
contributing factors.

Conclusion
Our study demonstrates that the use of SRS for spinal tumors results in a low VCF rate when using single-fraction
doses of 16 to 18 Gy. With continued research and
improved SRS protocols, toxicity rates can further decline,
and the role of spine SRS can become more prominent.
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